Cabaletta Bio, Inc. (CABA)

Cabaletta Bio is a clinical-stage biotech developing targeted B cell depletion therapies for autoimmune diseases, with its lead asset DSG3-CAART in active trials representing a potentially differentiated mechanism in a high-value indication. The analyst community is highly bullish — 8 of 10 analysts rate it Buy with a consensus price target of $13.25, implying ~327% upside from current levels. The primary risk is binary clinical-stage execution: any trial setback could be severely dilutive given the pre-revenue, cash-burning profile.

• Clinical trial readout for DSG3-CAART (pemphigus vulgaris indication) — interim or topline data could serve as a major near-term re-rating event
• Potential pipeline expansion announcements or IND filings for additional CAAR-T cell therapy targets across other autoimmune indications
• Upcoming quarterly update on cash runway and capital allocation, which could trigger positive sentiment if burn rate is better than expected or non-dilutive financing is secured

• Binary clinical risk: a failed or underwhelming DSG3-CAART trial readout could erase the majority of the stock's speculative premium, potentially driving the stock below $1.00
• Dilution risk: with no revenue and ongoing cash burn, equity offerings are likely necessary to fund operations, which could suppress share price materially
• Competitive risk: larger biopharma players with more resources are advancing CAR-T and B cell depletion platforms in autoimmune disease, potentially crowding out CABA's market opportunity

Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.

Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →